Several analysts have recently updated their ratings and price targets for Corcept Therapeutics (NASDAQ: CORT):

  • 9/5/2018 – Corcept Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/1/2018 – Corcept Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 8/30/2018 – Corcept Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 8/23/2018 – Corcept Therapeutics is now covered by analysts at Cantor Fitzgerald. They set a “neutral” rating and a $17.00 price target on the stock.
  • 8/19/2018 – Corcept Therapeutics was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating.
  • 8/13/2018 – Corcept Therapeutics was downgraded by analysts at ValuEngine from a “sell” rating to a “strong sell” rating.
  • 8/13/2018 – Corcept Therapeutics had its price target lowered by analysts at B. Riley from $30.00 to $22.00. They now have a “buy” rating on the stock.
  • 8/10/2018 – Corcept Therapeutics had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $11.00 price target on the stock, down previously from $20.00.
  • 8/7/2018 – Corcept Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/25/2018 – Corcept Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/19/2018 – Corcept Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 7/14/2018 – Corcept Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.

NASDAQ:CORT opened at $14.57 on Wednesday. The company has a market cap of $1.72 billion, a price-to-earnings ratio of 33.11 and a beta of 1.55. Corcept Therapeutics Incorporated has a twelve month low of $11.55 and a twelve month high of $25.96.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Thursday, August 9th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.04). Corcept Therapeutics had a net margin of 68.32% and a return on equity of 38.53%. The business had revenue of $62.31 million for the quarter, compared to analyst estimates of $68.49 million. During the same quarter in the previous year, the firm posted $0.13 earnings per share. The business’s revenue was up 75.2% on a year-over-year basis. equities analysts expect that Corcept Therapeutics Incorporated will post 0.6 earnings per share for the current year.

In other Corcept Therapeutics news, insider Robert S. Fishman sold 8,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, August 7th. The shares were sold at an average price of $14.15, for a total transaction of $113,200.00. Following the completion of the sale, the insider now directly owns 8,000 shares in the company, valued at approximately $113,200. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director G Leonard Baker, Jr. acquired 179,686 shares of the firm’s stock in a transaction on Wednesday, August 15th. The shares were acquired at an average price of $12.48 per share, with a total value of $2,242,481.28. Following the completion of the purchase, the director now owns 876,838 shares in the company, valued at approximately $10,942,938.24. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 321,159 shares of company stock valued at $4,025,880 and have sold 24,000 shares valued at $350,480. Insiders own 15.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in CORT. Tyers Asset Management LLC acquired a new stake in Corcept Therapeutics during the 1st quarter valued at approximately $136,000. Asset Management One Co. Ltd. acquired a new position in shares of Corcept Therapeutics in the 1st quarter valued at $150,000. Riverhead Capital Management LLC acquired a new position in shares of Corcept Therapeutics in the 1st quarter valued at $155,000. Flinton Capital Management LLC acquired a new position in shares of Corcept Therapeutics in the 1st quarter valued at $173,000. Finally, Stifel Financial Corp acquired a new position in shares of Corcept Therapeutics in the 1st quarter valued at $182,000. Institutional investors and hedge funds own 74.79% of the company’s stock.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.

Further Reading: Compound Annual Growth Rate (CAGR)

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.